China SXT Pharmaceuticals, Inc.
SXTC
Positions held
Your positionsSXTC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $453,907 | Enterprise value | -$27.06M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.00 | Beta | 1.86 | Dividend yield | 0.00% |
| Revenue growth | -43.9% | Earnings growth | — | Gross margin | 21.9% | Operating margin | -1.5% |
| Profit margin | 0.0% | ROE | -27.5% | ROA | -15.8% | Debt / equity | 0.04 |
| Current ratio | 7.94 | Free cash flow | -$4.74M | Analyst recommendation | none | Mean target | — |
| 52w high | $83,760.00 | 52w low | $0.31 |
Quarterly
No data yet.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | — |
| Op margin | -625.9% | -154.0% | -130.4% | -284.4% | — |
| Net income | -$6.2M | -$3.3M | -$3.1M | -$5.9M | — |
| Gross margin | 21.9% | 21.1% | 28.7% | 21.6% | — |
| Gross profit | $0.2M | $0.4M | $0.6M | $0.4M | — |
| Operating income | -$7.1M | -$2.7M | -$2.5M | -$5.6M | — |
Headlines — watch
• [WARN · balance sheet] China SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential
News
2026-10-09 · BC-Most Active Stocks
2026-10-08 · China SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential
2026-10-08 · China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
2026-10-08 · Top Premarket Decliners
2026-10-07 · BC-Most Active Stocks
2026-08-05 · BC-Most Active Stocks
2026-08-05 · China SXT Pharmaceuticals, Inc. Announces Share Consolidation
2026-08-05 · Top Premarket Decliners
2026-08-04 · BC-Most Active Stocks
2026-08-03 · BC-Most Active Stocks
2026-07-30 · BC-Most Active Stocks
2026-07-30 · Top Premarket Gainers
Price (daily)
Full chart · RSI · MACD · patterns